Shots:
Lupin, through its wholly owned subsidiary VISUfarma B.V., entered into an exclusive licensing agreement with Visus Therapeutics, a wholly owned subsidiary of Tenpoint Therapeutics, to commercialize YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for presbyopia in the European Union, United Kingdom, Switzerland, Norway, and Iceland
Under the agreement, VISUfarma will hold exclusive rights…
Shots:
Specialty medication access remains challenged by high costs, fragmented workflows, complex prior authorization requirements, and limited transparency, leading to delays, prescription drop-offs, and suboptimal patient outcomes.
DrFirst is addressing these gaps through AI-powered, workflow-integrated solutions that enable real-time benefits verification, targeted prior authorization automation, and smarter pharmacy routing, shifting care from reactive problem-solving to proactive, frictionless prescribing.
PharmaShots welcomes…

